Delivering Sustained Release of Peptide Therapeutics via a Subcutaneous Osmotic Mini-Pump
Scott Peterson
Executive Director, Business Development, Intarcia Therapeutics
The technology behind ITCA 650, an investigational therapy for T2DM and currently in Phase 3 of development, is an osmotic mini-pump that can deliver exenatide, a GLP-1 receptor agonist, subcutaneously for extended periods of time. This presentation will highlight the technology behind the Intarcia Osmotic Mini-Pump combined with in-vitro, in-vivo and human data generated with ITCA-650.